Contact Us / Request a Quote Download Manuals
Advanced Cell Diagnostics Advanced Cell Diagnostics

Search form

Please sign in
  • Log In
  • Register
  • How to Order
  • What to Buy
0 My Cart
X

You have no items in your shopping cart.

Menu
X
  • Products +
    RNAscope™/BaseScope™/ miRNAscope™
    +
    • Assay Selection Guide
    Target Probes
    +
    • All About Probes
    • Catalog Probes
    • Probe Sets
    • New Probe Request
    Manual Assays
    +
    RNAscope™ Chromogenic
    • Overview
    • RNAscope™ 2.5 HD Assay-Brown
    • RNAscope™ 2.5 HD Assay-Red
    • RNAscope™ 2.5 HD Duplex Assay
    RNAscope™ Multiplex Fluorescent
    • Overview
    • RNAscope™ HiPlex v2 Assay
    • RNAscope™ Multiplex Fluorescent V2
    BaseScope™
    • Overview
    • BaseScope™ Assay Red
    • BaseScope™ Duplex Assay
    miRNAscope™
    • Overview
    • miRNAscope™ Assay red
    • RNAscope™ Plus smRNA-RNA Assay
    DNAscope™
    • Overview
    • DNAscope™ Duplex Assay
    Automated Assays
    +
    For Lunaphore COMET™
    • RNAscope™ HiPlex Pro for COMET™
    For Leica systems
    • Overview
    • RNAscope™ 2.5 LS Assay-Brown
    • RNAscope™ 2.5 LS Assay-Red
    • RNAscope™ 2.5 LS Duplex Assay
    • RNAscope™ Multiomic LS Assay
    • RNAscope™ 2.5 LS Fluorescent Multiplex Assay
    • RNAscope™ 2.5 LSx Reagent Kit-BROWN
    • RNAscope™ 2.5 LSx Reagent Kit-RED
    • BaseScope™ LS Reagent Kit – RED
    • miRNAscope LS Reagent Kit Red
    • RNAscope™ Plus smRNA-RNA LS Assay
    Roche DISCOVERY ULTRA system
    • Overview
    • RNAscope™ VS Universal HRP
    • RNAscope™ VS Universal AP
    • RNAscope™ VS Duplex Assay
    • BaseScope™ VS Reagent Kit – RED
    RNA-Protein Co-Detection Assay
    +
    • RNAscope HiPlex-IMC™ Co-Detection
    • Integrated Codetection Assay
    • Sequential RNA Protein Detection
    Software
    +
    • Overview
    • Aperio RNA ISH Algorithm
    • HALO® image analysis platform
    Controls & Accessories
    +
    • RNAscope™
    • BaseScope™
    • miRNAscope™
    • Accessories
    How to Order
    +
    • Ordering Instructions
    • What to Buy
  • Services +
    Professional Assay Services
    +
    • Our Services
    • Multiomic Services
    • Biomarker Assay Development
    • Cell & Gene Therapy Services
    • Clinical Assay Development
    • Tissue Bank & Sample Procurement
    • Image Analysis
    Benefits
    +
    • Your Benefits
    • Certified Providers
    How to Order
    +
    • Ordering Process
    • Contact Services
  • Areas of Research +
    Most Popular
    +
    • COVID-19 Coronavirus
    • Single Cell Analysis
    • Whole-Mount
    • Anatomic Pathology Panels
    • Neuroscience
    • Inflammation
    • Gene Therapy/AAV
    • Stem Cell
    • Immuno-oncology
    • Liver Research
    • Cardiovascular & Skeletal Muscle Research
    Cell & Gene Therapy
    +
    • Gene Therapy
    • Gene Therapy/AAV
    • siRNA/ASO
    • Cell Therapy
    Cancer
    +
    • Breast Cancer
    • EGFRvIII Splice Variant
    • HPV Related Cancer
    • Immuno-oncology
    • Lung Cancer
    • PDx
    • Prostate Cancer
    • Point Mutation
    • CDR3 for TCR
    Viral
    +
    • COVID-19 Coronavirus
    • HIV & SIV
    • Infectious Disease
    • Zika Virus
    Pathways
    +
    • AKT
    • JAK STAT
    • WNT B-Catenin
    Neuroscience
    +
    Neuroscience
    • Neural Development
    • Neuronal Cell Types
    • Learning and Memory
    • G-protein-coupled Receptors & Ion Channels
    • Post-mortem Brain Tissue
    Other
    +
    • Circular RNA
    • Gene Fusions
    • HT Transcript Validation
    • Long Non-coding RNA
    • RNAseq Validation
    • Single Cell Analysis
    • Splice Variant
    • miRNA
    RNA & Protein
    +
    • Antibody Challenges
    • Dual ISH + IHC Methods
    • No Antibodies
    • RNA & Protein Analysis
    Customer Innovations
    +
    • Dual RNA+DNA ISH
    • Very old FFPE ISH
    • Wholemount ISH
    Animal Models
    +
    • Any Species
    • Mouse Model
    • Preclincal Safety
  • Technology +
    Overview
    +
    • How it Works
    • Data Image Gallery
    • Technology Video
    • Webinars
    RNA Detection
    +
    • Why RNA?
    • RNA ISH and IHC
    Pretreatment Options
    +
    • RNAscope™ Pretreatment
    • PretreatPro™
    Spotlights
    +
    • Researchers Spotlights
    • RNA & DNA
    • WISH
    • FFPE
    • Testimonials
    Publications, Guides & Posters
    +
    • Search publications
    • RNAscope™ Reference Guide
    • RNAscope™ Data Analysis Guide
    • Download RNAscope™ Posters
  • Support +
    Overview
    +
    • Get Started
    • How to Order
    • Distributors
    • Contact Support
    Troubleshooting
    +
    • Troubleshooting Guide
    • FAQs
    • User Manuals, SDS and Product Inserts
    • Documents and Downloads
    Imaging Resource
    +
    • Image Analysis
    • Image Registration Software
    • QuPath
    • HALO® image analysis platform
    Learn More
    +
    • Webinars
    • Training Videos
  • Partners +
    Partners
    +
    • Overview
    Partners Directory
    +
    Automation Partners
    • Leica Biosystem
    • Roche Diagnostics
    Workflow Partners
    • NanoString
    Software Partners
    • indica labs
    Become a Partner
    +
    • Learn How
  • Diagnostics +
    Diagnostics
    +
    • Diagnostics
    • Literature
    • Diagnostics ASR Probes
    • Diagnostics CE-IVD Probes
    • Diagnostics CE-IVD Detection
    • Companion Diagnostics
  • Image Calendar +
    Image Calendar
    +
    • Image Contest
    • Data Image Gallery
Search

Probes for HIV

ACD can configure probes for the various manual and automated assays for HIV for RNAscope Assay, or for Basescope Assay compatible for your species of interest.

  • Probes for HIV (60)
  • Kits & Accessories (0)
  • Support & Documents (0)
  • Publications (130)
  • Image gallery (0)
Refine Probe List

Content for comparison

Species

  • Human immunodeficiency virus 1 (37) Apply Human immunodeficiency virus 1 filter
  • HIV whole-genome vector AA1305#18 (8) Apply HIV whole-genome vector AA1305#18 filter
  • Other (1) Apply Other filter

Gene

  • HIV (61) Apply HIV filter
  • TBD (34) Apply TBD filter
  • SIV (14) Apply SIV filter
  • HTATSF1 (12) Apply HTATSF1 filter
  • HIV-1 (10) Apply HIV-1 filter
  • SIVmac239 (6) Apply SIVmac239 filter
  • HIV1 (5) Apply HIV1 filter
  • BA-V-HIV-vif-tat-3zz-st-sense (4) Apply BA-V-HIV-vif-tat-3zz-st-sense filter
  • BA-V-HIV-LTR-3zz-st-sense (4) Apply BA-V-HIV-LTR-3zz-st-sense filter
  • HIVgag (3) Apply HIVgag filter
  • Cd163 (2) Apply Cd163 filter
  • vpr (2) Apply vpr filter
  • HIV gag-pol (2) Apply HIV gag-pol filter
  • HIV  (2) Apply HIV  filter
  • HIV RNA (2) Apply HIV RNA filter
  • HIV DNA (2) Apply HIV DNA filter
  • Dkk3 (1) Apply Dkk3 filter
  • Axin2 (1) Apply Axin2 filter
  • GAPDH (1) Apply GAPDH filter
  • CD68 (1) Apply CD68 filter
  • CD4 (1) Apply CD4 filter
  • Dkk1 (1) Apply Dkk1 filter
  • CSF1R (1) Apply CSF1R filter
  • TSPY1 (1) Apply TSPY1 filter
  • IL34 (1) Apply IL34 filter
  • Dkk2 (1) Apply Dkk2 filter
  • Frzb (1) Apply Frzb filter
  • PDCD1 (1) Apply PDCD1 filter
  • BCL6 (1) Apply BCL6 filter
  • RRV (1) Apply RRV filter
  • RFHV (1) Apply RFHV filter
  • Sfrp2 (1) Apply Sfrp2 filter
  • Wif1 (1) Apply Wif1 filter
  • env (1) Apply env filter
  • IL-8 (1) Apply IL-8 filter
  • IFN-γ (1) Apply IFN-γ filter
  • IL-17A (1) Apply IL-17A filter
  • SIVMM32H (1) Apply SIVMM32H filter
  • IL-1β (1) Apply IL-1β filter
  • HIVgag-pol (1) Apply HIVgag-pol filter
  • pol (1) Apply pol filter
  • Slc12a3 (1) Apply Slc12a3 filter
  • nef (1) Apply nef filter
  • ADA (1) Apply ADA filter
  • HIV-1-gagpol (1) Apply HIV-1-gagpol filter
  • HHV5-IE (1) Apply HHV5-IE filter
  • HHV5-pp65 (1) Apply HHV5-pp65 filter
  • CD3 (1) Apply CD3 filter
  • Iba-1 (1) Apply Iba-1 filter
  • tat (1) Apply tat filter

Platform

  • Manual Assay RNAscope HiPlex (12) Apply Manual Assay RNAscope HiPlex filter
  • Automated Assay for Leica Systems - RNAscope (7) Apply Automated Assay for Leica Systems - RNAscope filter
  • Manual Assay RNAscope (5) Apply Manual Assay RNAscope filter
  • Manual Assay BaseScope (5) Apply Manual Assay BaseScope filter
  • Automated Assay for Ventana Systems - RNAscope (3) Apply Automated Assay for Ventana Systems - RNAscope filter
  • Automated Assay for Leica Systems - BaseScope (2) Apply Automated Assay for Leica Systems - BaseScope filter
  • Automated Assay for Ventana System - BaseScope (2) Apply Automated Assay for Ventana System - BaseScope filter

Channel

  • 1 (15) Apply 1 filter
  • 2 (9) Apply 2 filter
  • 3 (4) Apply 3 filter
  • 4 (4) Apply 4 filter
  • 6 (2) Apply 6 filter
  • 5 (1) Apply 5 filter

HiPlex Channel

  • T1 (2) Apply T1 filter
  • T10 (2) Apply T10 filter
  • T11 (2) Apply T11 filter
  • T12 (2) Apply T12 filter
  • T2 (2) Apply T2 filter
  • T3 (2) Apply T3 filter
  • T4 (2) Apply T4 filter
  • T5 (2) Apply T5 filter
  • T6 (2) Apply T6 filter
  • T7 (2) Apply T7 filter
  • T8 (2) Apply T8 filter
  • T9 (2) Apply T9 filter

Product

  • RNAscope 2.5 HD Red assay (16) Apply RNAscope 2.5 HD Red assay filter
  • RNAscope (12) Apply RNAscope filter
  • RNAscope 2.0 Assay (9) Apply RNAscope 2.0 Assay filter
  • RNAscope Multiplex Fluorescent Assay (9) Apply RNAscope Multiplex Fluorescent Assay filter
  • RNAscope 2.5 HD Brown Assay (8) Apply RNAscope 2.5 HD Brown Assay filter
  • TBD (6) Apply TBD filter
  • DNAscope HD Duplex Reagent Kit (5) Apply DNAscope HD Duplex Reagent Kit filter
  • RNAscope Fluorescent Multiplex Assay (5) Apply RNAscope Fluorescent Multiplex Assay filter
  • RNAscope 2.5 LS Assay (2) Apply RNAscope 2.5 LS Assay filter
  • BASEscope Assay RED (1) Apply BASEscope Assay RED filter
  • RNAscope 2.5 HD Duplex (1) Apply RNAscope 2.5 HD Duplex filter
  • RNAscope 2.5 HD Reagent Kit - BROWN (1) Apply RNAscope 2.5 HD Reagent Kit - BROWN filter
  • RNAscope Multiplex Fluorescent v2 (1) Apply RNAscope Multiplex Fluorescent v2 filter

Research area

  • HIV (64) Apply HIV filter
  • Infectious Disease (46) Apply Infectious Disease filter
  • Inflammation (24) Apply Inflammation filter
  • Neuroscience (12) Apply Neuroscience filter
  • Infectious (5) Apply Infectious filter
  • Stem cell (3) Apply Stem cell filter
  • Cancer (2) Apply Cancer filter
  • Immunology (2) Apply Immunology filter
  • Stem Cells (2) Apply Stem Cells filter
  • Addictions (1) Apply Addictions filter
  • AIDS (1) Apply AIDS filter
  • Animal Models (1) Apply Animal Models filter
  • Antimicrobial Chemotherapy (1) Apply Antimicrobial Chemotherapy filter
  • Antiretroviral therapy (1) Apply Antiretroviral therapy filter
  • CGT (1) Apply CGT filter
  • Covid (1) Apply Covid filter
  • Infectious Disease: HIV (1) Apply Infectious Disease: HIV filter
  • Liver (1) Apply Liver filter
  • Neuropathic pain (1) Apply Neuropathic pain filter
  • Signalling (1) Apply Signalling filter
  • SIV (1) Apply SIV filter
  • Substance Abuse disorders (1) Apply Substance Abuse disorders filter

Product sub type

  • Target Probes (16) Apply Target Probes filter

Category

  • Publications (130) Apply Publications filter
CD32-RNA Co-localizes with HIV-RNA in CD3+ Cells Found within Gut Tissues from Viremic and ART-Suppressed Individuals

Pathogens and Immunity

2019 May 03

Vasquez JJ, Aguilar-Rodriguez BL, Rodriguez L, Hogan LE, Somsouk M, McCune JM, Deeks SG, Laszik ZG, Hunt PW, Henrich TJ.
PMID: - | DOI: 10.20411/pai.v4i1.271

Abstract

Background: Identifying biomarkers for cells harboring replication-competent HIV is a major research priority. Recently, there have been mixed reports addressing the possibility that CD32-expressing T-cells are enriched for HIV. There is growing evidence that CD32 expression increases with cellular activation that may be related to, but not necessarily specific for, infection with HIV.  However, the relationship of CD32 expression to HIV-infection in subtypes of tissue-resident leukocytes is unclear. 

 Methods: First, we used duplex chromogenic in situ hybridization to identify cells actively transcribing RNA for both CD32 and HIV on human gut tissues. Then we performed multiplexed immunofluorescence and in situ hybridization (mIFISH) on sections from the same tissues to determine the phenotype of individual cells co-expressing HIV-RNA and CD32-RNA. 

 Results: HIV-RNA+ cells were more abundant in tissues from viremic individuals compared to those on suppressive anti-retroviral therapy (ART). However, staining by both methods indicated that a higher proportion of HIV-RNA+ cells co-expressed CD32-RNA in ART-suppressed compared to viremic individuals. The majority of HIV-RNA+ cells were CD3+.

Conclusions: Our data suggest that the transcription of CD32-RNA is correlated with HIV transcriptional activity in CD3+ cells found within human gut tissue. Whether or not up-regulation of CD32-RNA is a direct result of HIV reactivation or more global T cell activation remains unclear.

Persistent HIV transcription and variable antiretroviral drug penetration in lymph nodes during plasma viral suppression

AIDS (London, England)

2022 Jun 01

Fletcher, CV;Kroon, E;Schacker, T;Pinyakorn, S;Chomont, N;Chottanapund, S;Prueksakaew, P;Benjapornpong, K;Buranapraditkun, S;Phanuphak, N;Ananworanich, J;Vasan, S;Hsu, D;RV254/SEARCH 010 study Group, ;
PMID: 35184069 | DOI: 10.1097/QAD.0000000000003201

The ability of antiretroviral drugs to penetrate and suppress viral replication in tissue reservoir sites is critical for HIV remission. We evaluated antiretroviral concentrations in lymph nodes and their impact on HIV transcription.Participants of the RV254/SEARCH010 Acute HIV Infection Cohort in Thailand were enrolled. Group 1 (n  = 6) initiated and continued antiretrovirals with two nucleoside reverse transcriptase inhibitors (NRTIs), dolutegravir (DTG) and mar- aviroc (MVC). Group 2 (n = 12) initiated antiretrovirals with two NRTIs as well as efavirenz and were switched to two NRTIs as well as DTG. Antiretroviral concentrations were measured by mass spectroscopy. HIV RNA+ and DNA+ cells were measured by in-situ hybridization.All participants were MSM. At lymph node biopsy, all had plasma HIV RNA less than 20 copies/ml. Group 2 had longer durations of antiretroviral and DTG use (medians of 135 and 63 weeks, respectively) compared with Group 1 (median 44 weeks for both). TFV-DP, 3TC-TP, DTG and MVC were quantifiable in all lymph node samples from participants receiving those drugs versus carbovir-triphosphate (CBV-TP) in four out of 14. Median ratios of lymph node to peripheral blood concentrations were DTG, 0.014; MVC, 6.9; CBV-TP, 0.38; 3TC-TP, 0.32; and TFV-DP, 3.78. Median inhibitory quotients [ratios of lymph node concentrations to in-vitro inhibitory levels (IC50-or-90)] were DTG, 0.8; MVC, 38.8; CBV-TP, 0.5; 3TC- TP, 4.1; and TFV-DP, 1.8. Ongoing viral transcription was detected in lymph node of all participants. Median lymph node RNA+ cells were 71 350 versus 99 750 cells/g for Groups 1 and 2, respectively (P = 0.111).MVC has enhanced lymph node penetration and thereby may contribute to more complete viral suppression in the lymph node.
Establishment of A Novel Humanized Mouse Model To Investigate In Vivo Activation and Depletion of Patient-Derived HIV Latent Reservoirs.

J Virol. 2019 Jan 9.

2019 Jan 09

Flerin NC, Bardhi A, Zheng JH, Korom M, Folkvord J, Kovacs C, Benko E, Truong R, Mota T, Connick E, Jones RB, Lynch RM, Goldstein H.
PMID: PMID: 30626677 | DOI: DOI:10.1128/JVI.02051-18

Curing HIV infection has been thwarted by the persistent reservoir of latently-infected CD4+ T cells, which reinitiate systemic infection after antiretroviral therapy (ART) interruption. To evaluate reservoir-depletion strategies, we developed a novel pre-clinical in vivo model consisting of immunodeficient mice intrasplenically injected with peripheral blood mononuclear cells (PBMC) from long-term ART-suppressed HIV-infected donors. In the absence of ART, these mice developed rebound viremia which, two weeks after PBMC injection, was 1,000-fold higher (mean=9,229,281 HIV copies/ml) in mice injected intrasplenically than in mice injected intraperitoneally (mean=6,838 HIV copies/ml) or intravenously (mean=591 HIV copies/ml). One week after intrasplenic PBMC injection, in situ hybridization of the spleen demonstrated extensive disseminated HIV infection, likely initiated from in vivo reactivated primary latently infected cells. Time-to-viremia was delayed significantly by treatment with a broadly neutralizing antibody, 10-1074, as compared to treatment with 10-1074-FcRnull, suggesting that 10-1074 mobilized Fc-mediated effector mechanisms to deplete the replication-competent reservoir. This was supported by phylogenetic analysis of Env sequences from viral-outgrowth cultures and untreated, 10-1074-treated or 10-1074-FcRnull-treated mice. The predominant sequence cluster detected in viral-outgrowth cultures and untreated mouse plasma was significantly reduced in plasma of 10-1074-treated mice, while two new clusters emerged which were not detected in viral-outgrowth cultures or plasma from untreated mice. These new clusters lacked mutations associated with 10-1074 resistance. Taken together, these data indicated that 10-1074 treatment depletes the reservoir of latently infected cells harboring replication competent HIV. Furthermore, this mouse model represents a new in vivo approach for the preclinical evaluation of new HIV-cure strategies.IMPORTANCE Sustained remission of HIV infection is prevented by a persistent reservoir of latently infected cells capable of reinitiating systemic infection and viremia. To evaluate strategies to reactivate and deplete this reservoir, we developed and characterized a new humanized mouse model consisting of highly immunodeficient mice intrasplenically injected with peripheral blood mononuclear cells from long-term ART-suppressed HIV-infected donors. Reactivation and dissemination of HIV infection was visualized in the mouse spleens in parallel with the onset of viremia. The applicability of this model for evaluating reservoir depletion treatments was demonstrated by establishing, through delayed time-to-viremia and phylogenetic analysis of plasma virus, that treatment of these humanized mice with a broadly neutralizing antibody, 10-1074, depleted the patient-derived population of latently infected cells. This mouse model represents a new in vivo approach for the preclinical evaluation of new HIV-cure strategies.
Astrocytes are HIV reservoirs in the brain: A cell type with poor HIV infectivity and replication but efficient cell-to-cell viral transfer

Journal of neurochemistry

2021 Mar 02

Valdebenito, S;Castellano, P;Ajasin, D;Eugenin, EA;
PMID: 33655498 | DOI: 10.1111/jnc.15336

The major barrier to eradicating Human immunodeficiency virus-1 (HIV) infection is the generation of tissue-associated quiescent long-lasting viral reservoirs refractory to therapy. Upon interruption of anti-retroviral therapy (ART), HIV replication can be reactivated. Within the brain, microglia/macrophages and a small population of astrocytes are infected with HIV. However, the role of astrocytes as a potential viral reservoir is becoming more recognized because of the improved detection and quantification of HIV viral reservoirs. In this report, we examined the infectivity of human primary astrocytes in vivo and in vitro, and their capacity to maintain HIV infection, become latently infected, be reactivated, and transfer new HIV virions into neighboring cells. Analysis of human brain tissue sections obtained from HIV-infected individuals under effective and prolonged ART indicates that a small population of astrocytes has integrated HIV-DNA. In vitro experiments using HIV-infected human primary astrocyte cultures confirmed a low percentage of astrocytes had integrated HIV-DNA, with poor to undetectable replication. Even in the absence of ART, long-term culture results in latency that could be transiently reactivated with histone deacetylase inhibitor, tumor necrosis factor-alpha (TNF-α), or methamphetamine. Reactivation resulted in poor viral production but efficient cell-to-cell viral transfer into cells that support high viral replication. Together, our data provide a new understanding of astrocytes' role as viral reservoirs within the central nervous system (CNS).
The meningeal lymphatic system: a route for HIV brain migration?

J Neurovirol.

2015 Nov 16

Lamers SL, Rose R, Ndhlovu LC, Nolan DJ, Salemi M, Maidji E, Stoddart CA, McGrath MS.
PMID: 26572785 | DOI: -

Two innovative studies recently identified functional lymphatic structures in the meninges that may influence the development of HIV-associated neurological disorders (HAND). Until now, blood vessels were assumed to be the sole transport system by which HIV-infected monocytes entered the brain by bypassing a potentially hostile blood-brain barrier through inflammatory-mediated semi-permeability. A cascade of specific chemokine signals promote monocyte migration from blood vessels to surrounding brain tissues via a well-supported endothelium, where the cells differentiate into tissue macrophages capable of productive HIV infection. Lymphatic vessels on the other hand are more loosely organized than blood vessels. They absorb interstitial fluid from bodily tissues where HIV may persist and exchange a variety of immune cells (CD4+ T cells, monocytes, macrophages, and dendritic cells) with surrounding tissues through discontinuous endothelial junctions. We propose that the newly discovered meningeal lymphatics are key to HIV migration among viral reservoirs and brain tissue during periods of undetectable plasma viral loads due to suppressive combinational antiretroviral therapy, thus redefining the migration process in terms of a blood-lymphatic transport system.

Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells

Cell Reports

2017 Jul 25

Cavrois M, Banerjee T, Mukherjee G, Raman N, Hussien R, Rodriguez BA, Vasquez J, Spitzer MH, Lazarus NH, Jones JJ, Ochsenbauer C, McCune JM, Butcher EC, Arvin AM, Sen N, Greene WC, Roan NR.
PMID: 28746881 | DOI: 10.1016/j.celrep.2017.06.087

To characterize susceptibility to HIV infection, we phenotyped infected tonsillar T cells by single-cell mass cytometry and created comprehensive maps to identify which subsets of CD4+ T cells support HIV fusion and productive infection. By comparing HIV-fused and HIV-infected cells through dimensionality reduction, clustering, and statistical approaches to account for viral perturbations, we identified a subset of memory CD4+ T cells that support HIV entry but not viral gene expression. These cells express high levels of CD127, the IL-7 receptor, and are believed to be long-lived lymphocytes. In HIV-infected patients, CD127-expressing cells preferentially localize to extrafollicular lymphoid regions with limited viral replication. Thus, CyTOF-based phenotyping, combined with analytical approaches to distinguish between selective infection and receptor modulation by viruses, can be used as a discovery tool.

Cytolytic CD8+ T cells infiltrate germinal centers to limit ongoing HIV replication in spontaneous controller lymph nodes

Science immunology

2023 May 19

Collins, DR;Hitschfel, J;Urbach, JM;Mylvaganam, GH;Ly, NL;Arshad, U;Racenet, ZJ;Yanez, AG;Diefenbach, TJ;Walker, BD;
PMID: 37205767 | DOI: 10.1126/sciimmunol.ade5872

Follicular CD8+ T cells (fCD8) mediate surveillance in lymph node (LN) germinal centers against lymphotropic infections and cancers, but the precise mechanisms by which these cells mediate immune control remain incompletely resolved. To address this, we investigated functionality, clonotypic compartmentalization, spatial localization, phenotypic characteristics, and transcriptional profiles of LN-resident virus-specific CD8+ T cells in persons who control HIV without medications. Antigen-induced proliferative and cytolytic potential consistently distinguished spontaneous controllers from noncontrollers. T cell receptor analysis revealed complete clonotypic overlap between peripheral and LN-resident HIV-specific CD8+ T cells. Transcriptional analysis of LN CD8+ T cells revealed gene signatures of inflammatory chemotaxis and antigen-induced effector function. In HIV controllers, the cytotoxic effectors perforin and granzyme B were elevated among virus-specific CXCR5+ fCD8s proximate to foci of HIV RNA within germinal centers. These results provide evidence consistent with cytolytic control of lymphotropic infection supported by inflammatory recruitment, antigen-specific proliferation, and cytotoxicity of fCD8s.
HIV transmitting mononuclear phagocytes; integrating the old and new

Mucosal immunology

2022 Feb 16

Vine, EE;Rhodes, JW;Warner van Dijk, FA;Byrne, SN;Bertram, KM;Cunningham, AL;Harman, AN;
PMID: 35173293 | DOI: 10.1038/s41385-022-00492-0

In tissue, mononuclear phagocytes (MNP) are comprised of Langerhans cells, dendritic cells, macrophages and monocyte-derived cells. They are the first immune cells to encounter HIV during transmission and transmit the virus to CD4 T cells as a consequence of their antigen presenting cell function. To understand the role these cells play in transmission, their phenotypic and functional characterisation is important. With advancements in high parameter single cell technologies, new MNPs subsets are continuously being discovered and their definition and classification is in a state of flux. This has important implications for our knowledge of HIV transmission, which requires a deeper understanding to design effective vaccines and better blocking strategies. Here we review the historical research of the role MNPs play in HIV transmission up to the present day and revaluate these studies in the context of our most recent understandings of the MNP system.
The active human immunodeficiency virus reservoir during antiretroviral therapy: emerging players in viral persistence

Current opinion in HIV and AIDS

2021 Jul 01

Astorga-Gamaza, A;Buzon, MJ;
PMID: 33973900 | DOI: 10.1097/COH.0000000000000685

To discuss the role of CD4+ T cells with active Human immunodeficiency virus (HIV), meaning infected cells with transcriptional and/or translational viral activity during antiretroviral therapy (ART), focusing on new technologies for its detection, potential cell markers for its characterization, and evidences on the contribution of the active HIV reservoir to long-term viral persistence.HIV-infected cells expressing viral ribonucleic acid are systematically detected in subjects on long-term ART. In recent years, powerful new tools have provided significant insights into the nature, quantification, and identification of cells with active HIV, including the identification of new cell markers, and the presence of viral activity in specific cell populations located in different cellular and anatomical compartments. Moreover, studies on viral sequence integrity have identified cell clones with intact viral genomes and active viral transcription that could potentially persist for years. Together, new investigations support the notion that the active reservoir could represent a relevant fraction of long-term infected cells, and therefore, the study of its cell sources and mechanisms of maintenance could represent a significant advance in our understanding of viral persistence and the development of new curative strategies.The presence of HIV-infected cells with viral expression during ART has been traditionally overlooked for years. Based on recent investigations, this active viral reservoir could play an important role in HIV persistence.
Effects of Daily Discrimination on Pain, Mood, and Sleep in People Living with HIV

The Journal of Pain

2022 May 01

Hobson, J;Gilstrap, S;Ho, M;Fehrmann, N;Gathright, J;White, D;Thomas, J;Goodin, B;Cody, S;
| DOI: 10.1016/j.jpain.2022.03.140

Emerging literature suggests that experiences of discrimination negatively influence health and well-being. It is unfortunately common for people living with HIV (PLWH) to be stigmatized and discriminated against because of their HIV status and other marginalized identities (e.g., ethnicity/race, sexual identity and orientation). To date, little research has specifically examined discrimination in PWLH and its associations with pain and other pain-relevant factors such as mood and sleep. The purpose of this ongoing study was to preliminarily analyze associations among daily experiences of discrimination, pain severity and interference, depressive symptoms, and sleep in PLWH. Participants included 24 PLWH recruited from a local HIV treatment center. Participants completed The Everyday Discrimination Scale (TEDS) followed by the Brief Pain Inventory - Short Form (BPI-SF), the Insomnia Severity Index (ISI), and the Center for Epidemiologic Studies - Depression Scale (CES-D). Initial findings tentatively suggest that more frequent daily experiences of discrimination may be significantly associated with greater pain interference on the BPI-SF (p = .030) and greater severity of insomnia symptoms on the ISI (p = .059). However, it appears that daily experiences of discrimination may not be meaningfully associated with pain severity on the BPI-SF (p = .401) or depressive symptoms on the CES-D (p = .235). Our findings highlight the potentially deleterious effects of daily discrimination experiences on pain and sleep in in PLWH. As this ongoing study recruits a larger sample of PLWH, data will need to be reanalyzed to better determine the durability of these preliminary findings. However, there is potential that findings from this study may assist in elucidating causal pathways linking discrimination to pain and pain relevant health behaviors like sleep in PLWH. Grant support from The Impact of Insomnia on Pain, Physical Function, and Inflammation in HIV (3R01HL147603-03S1).
CD4+ T cells in HIV: A Friend or a Foe? A double-edged sword

Frontiers in Immunology

2023 Jan 01

Govindaraj, S;Babu, H;Sidharthan, SK;Vaccari, M;
| DOI: 10.3389/fimmu.2023.1203531

Currently, there are approximately 38.4 million individuals living with the Human Immunodeficiency Virus (HIV), of which 36.7 million adults, 1.7 million children (
ITEM
BaseScope™ Probe- BA-V-HIV-TatRev-2EJ-C2 ?
Cat No. 702371-C2
Manual Assay BaseScope

Log In to see price

Add to compare
Compare
Request a Quote
  • View Details

    Specifications

    Gene :HIV
    Species* :Other
    Species (common):Unclassified
    Entrez Gene ID :N/A
    Gene Alias :N/A
    Accession No :N/A
    Target Region [Base Pairs (bp)] :267 - 570
    No. of Pairs :2
    Assay Compatibility :N/A
    Shipping Temp :2-8 C
    Storage Temp :2-8 C
    Shelf Life :24 months from the date of manufacturing
    * Please check expiration dates on the reagent package
    Probe description :BaseScope™ Probe - BA-V-HIV-TatRev-2EJ-C2 - NL43 Tat Rev (HIV) target SD1-SA3 junction and D4-A7 junction
    Channel :2
    RNAscope™ Assay Platform :Manual Assay BaseScope
  • Assay Compatibility
    Unclassified
  • Recommended Controls
  • Product Insert/Data Sheet
    No Related Documents...

Specifications

Gene :HIV
Species* :Other
Species (common):Unclassified
Entrez Gene ID :N/A
Gene Alias :N/A
Accession No :N/A
Target Region [Base Pairs (bp)] :267 - 570
No. of Pairs :2
Assay Compatibility :N/A
Shipping Temp :2-8 C
Storage Temp :2-8 C
Shelf Life :24 months from the date of manufacturing
* Please check expiration dates on the reagent package
Probe description :BaseScope™ Probe - BA-V-HIV-TatRev-2EJ-C2 - NL43 Tat Rev (HIV) target SD1-SA3 junction and D4-A7 junction
Channel :2
RNAscope™ Assay Platform :Manual Assay BaseScope
Unclassified
No Related Documents...

Pages

  • « first
  • ‹ previous
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • next ›
  • last »
X
Description
sense
Example: Hs-LAG3-sense
Standard probes for RNA detection are in antisense. Sense probe is reverse complent to the corresponding antisense probe.
Intron#
Example: Mm-Htt-intron2
Probe targets the indicated intron in the target gene, commonly used for pre-mRNA detection
Pool/Pan
Example: Hs-CD3-pool (Hs-CD3D, Hs-CD3E, Hs-CD3G)
A mixture of multiple probe sets targeting multiple genes or transcripts
No-XSp
Example: Hs-PDGFB-No-XMm
Does not cross detect with the species (Sp)
XSp
Example: Rn-Pde9a-XMm
designed to cross detect with the species (Sp)
O#
Example: Mm-Islr-O1
Alternative design targeting different regions of the same transcript or isoforms
CDS
Example: Hs-SLC31A-CDS
Probe targets the protein-coding sequence only
EnEmProbe targets exons n and m
En-EmProbe targets region from exon n to exon m
Retired Nomenclature
tvn
Example: Hs-LEPR-tv1
Designed to target transcript variant n
ORF
Example: Hs-ACVRL1-ORF
Probe targets open reading frame
UTR
Example: Hs-HTT-UTR-C3
Probe targets the untranslated region (non-protein-coding region) only
5UTR
Example: Hs-GNRHR-5UTR
Probe targets the 5' untranslated region only
3UTR
Example: Rn-Npy1r-3UTR
Probe targets the 3' untranslated region only
Pan
Example: Pool
A mixture of multiple probe sets targeting multiple genes or transcripts

Enabling research, drug development (CDx) and diagnostics

Contact Us
  • Toll-free in the US and Canada
  • +1877 576-3636
  • 
  • 
  • 
Company
  • Overview
  • Leadership
  • Careers
  • Distributors
  • Quality
  • News & Events
  • Webinars
  • Patents
Products
  • RNAscope or BaseScope
  • Target Probes
  • Controls
  • Manual assays
  • Automated Assays
  • Accessories
  • Software
  • How to Order
Research
  • Popular Applications
  • Cancer
  • Viral
  • Pathways
  • Neuroscience
  • Other Applications
  • RNA & Protein
  • Customer Innovations
  • Animal Models
Technology
  • Overview
  • RNA Detection
  • Spotlight Interviews
  • Publications & Guides
Assay Services
  • Our Services
  • Biomarker Assay Development
  • Cell & Gene Therapy Services
  • Clinical Assay Development
  • Tissue Bank & Sample Procurement
  • Image Analysis
  • Your Benefits
  • How to Order
Diagnostics
  • Diagnostics
  • Companion Diagnostics
Support
  • Getting started
  • Contact Support
  • Troubleshooting Guide
  • FAQs
  • Manuals, SDS & Inserts
  • Downloads
  • Webinars
  • Training Videos

Visit Bio-Techne and its other brands

  • bio-technie
  • protein
  • bio-spacific
  • rd
  • novus
  • tocris
© 2025 Advanced Cell Diagnostics, Inc.
  • Terms and Conditions of Sale
  • Privacy Policy
  • Security
  • Email Preferences
  • 
  • 
  • 

For Research Use Only. Not for diagnostic use. Refer to appropriate regulations. RNAscope is a registered trademark; and HybEZ, EZ-Batch and DNAscope are trademarks of Advanced Cell Diagnostics, Inc. in the United States and other countries. All rights reserved. ©2025 Advanced Cell Diagnostics, Inc.

 

Contact Us / Request a Quote
Download Manuals
Request a PAS Project Consultation
Order online at
bio-techne.com
OK
X
Contact Us

Complete one of the three forms below and we will get back to you.

For Quote Requests, please provide more details in the Contact Sales form below

  • Contact Sales
  • Contact Support
  • Contact Services
  • Offices

Advanced Cell Diagnostics

Our new headquarters office starting May 2016:

7707 Gateway Blvd.  
Newark, CA 94560
Toll Free: 1 (877) 576-3636
Phone: (510) 576-8800
Fax: (510) 576-8798

 

Bio-Techne

19 Barton Lane  
Abingdon Science Park
Abingdon
OX14 3NB
United Kingdom
Phone 2: +44 1235 529449
Fax: +44 1235 533420

 

Advanced Cell Diagnostics China

20F, Tower 3,
Raffles City Changning Office,
1193 Changning Road, Shanghai 200051

021-52293200
info.cn@bio-techne.com
Web: www.acdbio.com/cn

For general information: Info.ACD@bio-techne.com
For place an order: order.ACD@bio-techne.com
For product support: support.ACD@bio-techne.com
For career opportunities: hr.ACD@bio-techne.com

See Distributors
×

You have already Quick ordered an Item in your cart . If you want to add a new item , Quick ordered Item will be removed form your cart. Do You want to continue?

OK Cancel
Need help?

How can we help you?